Management of Bronchiectasis with Eosinophilic COPD
For patients with bronchiectasis and eosinophilic COPD, treat both conditions according to their respective evidence-based guidelines: use triple inhaler therapy (LABA+LAMA+ICS) for the eosinophilic COPD component when blood eosinophils are ≥300 cells/µL with frequent exacerbations, while simultaneously implementing bronchiectasis-specific airway clearance techniques and avoiding ICS if bronchiectasis is the sole indication. 1, 2
Diagnostic Clarification First
Before initiating treatment, you must correctly identify whether true COPD coexists with bronchiectasis using the ROSE criteria 1:
- Radiological bronchiectasis on CT
- Obstruction (FEV₁/FVC <0.7)
- Appropriate Symptoms
- Appropriate Exposures (typically smoking history)
This distinction is critical because misdiagnosis of bronchiectasis as COPD is common, and inappropriate ICS use in bronchiectasis-only patients increases pneumonia and non-tuberculous mycobacterial (NTM) infection risk 1.
Blood Eosinophil-Guided Treatment Algorithm
If Blood Eosinophils ≥300 cells/µL AND ≥3 Exacerbations/Year:
- Initiate triple therapy (LABA+LAMA+ICS) 2, 3
- This combination reduces exacerbations and may provide mortality benefit in eosinophilic COPD 2
- The higher the eosinophil count, the greater the expected ICS benefit 3
If Blood Eosinophils 100-300 cells/µL AND Frequent Exacerbations:
- Consider triple therapy - the evidence supports potential benefit in this range 3
- Weigh against bronchiectasis-related ICS risks (pneumonia, NTM infection) 1
If Blood Eosinophils <100 cells/µL OR No Frequent Exacerbations:
- Use dual bronchodilation (LABA+LAMA) only 2, 3
- Avoid ICS - the bronchiectasis guidelines explicitly recommend against routine ICS use without clear COPD/asthma indication 1, 4
Bronchiectasis-Specific Management (Concurrent with COPD Treatment)
Airway Clearance - Non-Negotiable Foundation:
- Refer to respiratory physiotherapist for individualized airway clearance technique 4
- Implement oscillating positive expiratory pressure (OPEP) devices 5
- Consider mucoactive agents (carbocysteine) with 6-month trial if difficulty expectorating 4
- Pre-treat with bronchodilator before nebulized treatments to prevent bronchoconstriction 4
Pulmonary Rehabilitation:
- Strongly recommended for breathlessness and/or impaired exercise capacity 1
- Must include bronchiectasis-specific education and airway clearance strategies 1
Sputum Microbiology Surveillance:
- Regular sputum culture for routine bacteriology AND fungal culture 4
- Three sputum samples for mycobacterial culture if clinical deterioration 4
- If Pseudomonas aeruginosa colonization with ≥3 exacerbations/year: consider inhaled colistin 4
Critical Pitfalls to Avoid
ICS Overuse Risk: The 2025 ERS bronchiectasis guideline emphasizes that 20-30% of bronchiectasis patients have comorbid COPD, but ICS should only be prescribed when COPD criteria are met with appropriate eosinophil levels 1. Between 20-30% of patients have ICS-related adverse events including pneumonia and NTM infection 1.
Monitoring Requirement: If ICS are used, formally evaluate treatment effectiveness after a defined period and discontinue if ineffective or causing harm 1. This is particularly important given the dual disease burden.
Emerging Therapies for Refractory Cases
If symptoms persist despite optimized triple therapy in eosinophilic phenotype:
- Dupilumab has demonstrated exacerbation reduction in eosinophilic COPD 2, 3, 6
- Consider only after maximizing conventional therapy
- Evidence is emerging but shows promise for this specific phenotype 3
Disease Monitoring Parameters
Assess at each visit:
- Exacerbation frequency (triggers long-term antibiotic consideration at ≥3/year) 4
- Sputum volume and purulence changes
- Blood eosinophil trends (guides ICS continuation)
- Oxygen saturation and spirometry 4
- Signs of NTM infection or pneumonia (ICS complications) 1
The key principle is treating the eosinophilic COPD component with appropriate inhaled therapy while simultaneously addressing bronchiectasis through airway clearance and infection prevention, recognizing these are distinct but coexisting conditions requiring parallel management strategies.